Hanmin Wang

Mr. Hanmin Wang

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in European Journal of Pharmacology
Verified
Journal Article
Closed access
ZYZhang Yang
Zhang Yang
CWChen Weian
Chen Weian
HSHuang Susu
Huang Susu
HWHanmin Wang
Hanmin Wang

22 November 2018 in Developmental Dynamics
Verified
Journal Article
Open access
PDF file
HWHanmin Wang
Hanmin Wang
JUJuli Unternaehrer
Juli Unternaehrer
In this review, we explore the connections between epithelial‐mesenchymal transition (EMT) and differentiation status. EMTs in development have been described as differentiation events, while in most cases EMTs in cancer have been depicted as dedifferentiation events. We will briefly summarize both embryo development and cancer progression with regard to the involvement of EMT and cell differentiation status. We further present the studies that provide evidence that EMT results in both differentiation and dedifferentiation. Finally, we present our resolution to this dilemma by suggesting that EMT brings about dedifferentiation that enables subsequent differentiation. In normal development, EMT events may cause a partial reversal of differentiation to overcome differentiation barriers. When EMT is aberrantly activated in cancer, cells gain attributes of stem cells that contribute to self‐renewal capabilities and are able to differentiate to all cell types represented in the tumor. The resulting cancer stem cells attain hallmarks of cancer, including replicative immortality, resistance to cell death, and invasiveness. Developmental Dynamics 248:10–20, 2019.

23 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
HWHanmin Wang
Hanmin Wang
ECEvgeny Chirshev
Evgeny Chirshev
NHNozomi Hojo
Nozomi Hojo
TSTise Suzuki
Tise Suzuki
ABAntonella Bertucci
Antonella Bertucci
JUJuli Unternaehrer
Juli Unternaehrer
We aimed to determine the mechanism of epithelial–mesenchymal transition (EMT)-induced stemness in cancer cells. Cancer relapse and metastasis are caused by rare stem-like cells within tumors. Studies of stem cell reprogramming have linked let-7 repression and acquisition of stemness with the EMT factor, SNAI1. The mechanisms for the loss of let-7 in cancer cells are incompletely understood. In four carcinoma cell lines from breast cancer, pancreatic cancer, and ovarian cancer and in ovarian cancer patient-derived cells, we analyzed stem cell phenotype and tumor growth via mRNA, miRNA, and protein expression, spheroid formation, and growth in patient-derived xenografts. We show that treatment with EMT-promoting growth factors or SNAI1 overexpression increased stemness and reduced let-7 expression, while SNAI1 knockdown reduced stemness and restored let-7 expression. Rescue experiments demonstrate that the pro-stemness effects of SNAI1 are mediated via let-7. In vivo, nanoparticle-delivered siRNA successfully knocked down SNAI1 in orthotopic patient-derived xenografts, accompanied by reduced stemness and increased let-7 expression, and reduced tumor burden. Chromatin immunoprecipitation demonstrated that SNAI1 binds the promoters of various let-7 family members, and luciferase assays revealed that SNAI1 represses let-7 transcription. In conclusion, the SNAI1/let-7 axis is an important component of stemness pathways in cancer cells, and this study provides a rationale for future work examining this axis as a potential target for cancer stem cell-specific therapies.

15 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
ECEvgeny Chirshev
Evgeny Chirshev
TSTise Suzuki
Tise Suzuki
HWHanmin Wang
Hanmin Wang
ANAnthony Nguyen
Anthony Nguyen
NHNozomi Hojo
Nozomi Hojo
JUJuli Unternaehrer
Juli Unternaehrer
High-grade serous carcinoma of the ovary is a deadly gynecological cancer with poor long-term survival. Dysregulation of microRNAs has been shown to contribute to the formation of cancer stem cells (CSCs), an important part of oncogenesis and tumor progression. The let-7 family of microRNAs has previously been shown to regulate stemness and has tumor suppressive actions in a variety of cancers, including ovarian. Here, we demonstrate tumor suppressor actions of let-7i: repression of cancer cell stemness, inhibition of migration and invasion, and promotion of apoptosis, features important for cancer progression, relapse, and metastasis. Let-7i over-expression results in increased sensitivity to the PARP inhibitor olaparib in samples without BRCA mutations, consistent with induction of BRCAness phenotype. We also show that let-7i inhibits the expression of several factors involved in the homologous recombination repair (HRR) pathway, providing potential mechanisms by which the BRCAness phenotype could be induced. These actions of let-7i add to the rationale for use of this miRNA as a treatment for ovarian cancer patients, including those without mutations in the HRR pathway.

22 July 2021 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
PDF file
YYYu Yao
Yu Yao
XLXiang Li
Xiang Li
JLJie Lin
Jie Lin
XZXu Zhang
Xu Zhang
HWHanmin Wang
Hanmin Wang

1 November 2006 in Public Health
Verified
Journal Article
Closed access
YLYa-Ling Liu
Ya-Ling Liu
HWHanmin Wang
Hanmin Wang
XWXia Wang
Xia Wang
MDMin-Xia Dai
Min-Xia Dai
LSLei Shang
Lei Shang
YXYong-Yong Xu
Yong-Yong Xu